Good Great. morning, Thanks, everyone. John.
where of and slide September we the such through for markets with go world. to XX. launch the new X on me Let most XX number very progress launch as countries We're including Japan, United pleased year, Australia, recently snapshot States into a reimbursed this of the Galafold the countries through Galafold for begin bringing the total around Galafold
a the over revenue third quarter from increase was of XX% Our approximately million, quarter year third XXXX. $XX.X year
at As in a Analyst in patterns by and discuss Day mentioned October release revenue uneven was which I'll our moment. further growth ordering press in impacted we in sequential this morning, discussed our Europe,
to great come quarter quarter, relative exceed know fourth and in we as well. that already launch patterns along with will we the US now stabilize, expectations, Japan progress to As the continues ordering to third
variants XXX the label with US patients now described list. today reminder the XXX firmly or range, to full nearly track a which pharmacogenetic million the we're they’re initial our gene as double approval, $XX from year initially of at XXX Fabry versus treating become approach added more So importantly, US our mutations in the come XXX to vision higher on to And mutations ever our revenue last first guidance amenable new with gene label in and million now has since than of amenable end European $XX to as represents in reality a offering the year. variants the
population. countries, me little EUX continued patients more throughout progress. strong amenable now international on of XX% Turning to which treated to the Fabry European share than a have very slide of bit Europe the a see within X, lion's detail let penetration our share and share more We've market represents the
Galafold. the mature these markets patients initial opportunities the see in to come continue well portion begin launch the share on XX% north market see we future to diagnosed, UK, treated countries, amenable as in of patients of untreated increasing Germany more Importantly, but is and like growth of we and to
high not patients, only the of see switch are market untreated the to these we So often time. patients therapy a to now first for growing also by continuing on bringing we're number
markets regimen see see uptake across diagnosed in represents which We from then long our in of and patients, patterns the continue expect at an the to see switch Analyst that markets, finally, uneven October untreated and extremely relatively Day continued a pattern well, and our started in And compliance opportunity. early are high growth ordering oral to as and to this in to continue alluded adherence we we treatment patients adoption term newer this all significant as that to to again third rate new quarter, we market.
with high one the heading we're continues month rates, shift and summer in very adherence to as markets example, from the of into compliance particularly prescriptions, larger three adoption some seeing month months. For a
have treatment advance almost option offers as we're travels Coming While touch the patterns, in extremely and which summer fourth expecting we stock and let this for generally reality finish very is to quarter, progress normalized think me patterns a moving can to new oral the the ordering uneven United patients ability positive And States, going X, with to up the in with the year. a in of on slide an it create that holidays. on the launch well. ordering of to strong
was Galafold a tracking our of October. our total or Day a PRFs, exceeded demand in in referral based of the key been launch have patient we at significantly introduced patients October on of launch metric in on United As which Germany. forecast, as States prescribed XXX which XX, our based initial forms Analyst the successful This
after US in our US XX you which So prescriber from of PRFs there this as this we graph of see forecast, built of with launch XXX four well. well predicted United study patients initial against highlighted drug, a can we here just our than the a Analyst illustrates physicians, comes German non-study what very all new strong will XXst, foundation plotted in prescribed market number forecast, XXXX. shipment a is months more the approximately dynamics, includes patients as XX-day of XXXX, And of of conversion ahead Galafold. launch this now revenue the a of point, the And approximately reminder, patients will that at we're States. we broad again that, impact October limited and Day as in as our to October, PRF base of XX while as see And time average from XX we significant for includes set given our
as turn our let an provide to I the and community. on that call the that, launch With Fabry from to update the track in we our million $XX our to to on based full let on million. achieve me this Finally, year turning range confident the ability slide objective to enthusiasm that reiterate outlined from the just dynamics of We're well and Japan growth the Chip guidance me of continued to success US just $XX and achieve international end the higher are the back in as XX, team financials.
